Impact of RFA on Esophageal Distensibility and Mucosal Impedance
A legfontosabb adatok
- Hol
- Rochester (Egyesült Államok)A helyszín megnézése
Helyszínek itt: Egyesült Államok
- Mayo ClinicRochester, Egyesült ÁllamokContact: Mariah J. RobranRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Mayo Clinic
- Azonosító
- NCT07126535
- A regiszteradat frissítve
- 2026. október 14.
- Eredeti leírás
Patients undergoing ablative therapy for management of dysplastic Barrett's Esophagus (BE) will have decreased distensibility over the course of treatment, but improvement in mucosal impedance as BE epithelia is replaced by neosquamous epithelia. This information may lead to further research in predicting therapeutic response and complications. The purpose of this research is to collect information while measuring changes related to the esophagus in patients that receive radiofrequency ablation (RFA) for dysplastic Barrett's Esophagus (BE) or esophageal cancer. Study participation includes measurements of the esophagus with the use of two different devices. This takes place during clinically indicated upper endoscopies during the timeframe the participant is receiving RFA treatments. This process will take up to an additional 10 minutes during the upper endoscopy and be done while the participant is sedated.A teljes eredeti leírásKevesebb
Assessment of Esophageal Distensibility and Mucosal Impedance in Dysplastic Barrett's Esophagus Patients Undergoing Radiofrequency Ablation
Patients undergoing ablative therapy for management of dysplastic Barrett's Esophagus (BE) will have decreased distensibility over the course of treatment, but improvement in mucosal impedance as BE epithelia is replaced by neosquamous epithelia. This information may lead to further research in predicting therapeutic response and complications. The purpose of this research is to collect information while measuring changes related to the esophagus in patients that receive radiofrequency ablation (RFA) for dysplastic Barrett's Esophagus (BE) or esophageal cancer. Study participation includes measurements of the esophagus with the use of two different devices. This takes place during clinically indicated upper endoscopies during the timeframe the participant is receiving RFA treatments. This process will take up to an additional 10 minutes during the upper endoscopy and be done while the participant is sedated.
Bevonási feltételek: Male or female ≥ 18 years of age; Confirmed histologic diagnosis of BE with dysplasia or intramucosal carcinoma (IMCa); Ability to take high-dose proton pump inhibitor (PPI) therapy (such as omeprazole 40 mg BID); Willing to undergo multiple rounds of endoscopic eradication therapy (EET) for management of BE (which is the guideline clinical recommendation for management of this disease).
Kizáró feltételek: History of esophageal cancer treated with radiation or chemotherapy; Received injection of glucagon like peptide 1 agonists within a few days prior to EGD; History of esophageal ablation; History of esophageal stricture; History of esophageal or gastric surgery; History of achalasia; History of delayed gastric emptying confirmed by 4-hour gastric emptying study; Pregnancy; Adults lacking the capacity to consent for self.